MX2017012822A - Composiciones que contienen ibrutinib. - Google Patents

Composiciones que contienen ibrutinib.

Info

Publication number
MX2017012822A
MX2017012822A MX2017012822A MX2017012822A MX2017012822A MX 2017012822 A MX2017012822 A MX 2017012822A MX 2017012822 A MX2017012822 A MX 2017012822A MX 2017012822 A MX2017012822 A MX 2017012822A MX 2017012822 A MX2017012822 A MX 2017012822A
Authority
MX
Mexico
Prior art keywords
sodium
lymphoma
compositions
ibrutinib
metabolite
Prior art date
Application number
MX2017012822A
Other languages
English (en)
Spanish (es)
Inventor
Kumar Gupta Manish
Gole Dilip
Tambwekar Kaustubh
Krishnan Nair Binuraj
Bernini Maristella
Inghelbrecht Sabine
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017012822(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2017012822A publication Critical patent/MX2017012822A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/10—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/22—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017012822A 2015-04-06 2016-04-06 Composiciones que contienen ibrutinib. MX2017012822A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06
PCT/US2016/026134 WO2016164404A1 (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib

Publications (1)

Publication Number Publication Date
MX2017012822A true MX2017012822A (es) 2018-06-13

Family

ID=55806788

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012822A MX2017012822A (es) 2015-04-06 2016-04-06 Composiciones que contienen ibrutinib.
MX2021015250A MX2021015250A (es) 2015-04-06 2017-10-05 Composiciones que contienen ibrutinib.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015250A MX2021015250A (es) 2015-04-06 2017-10-05 Composiciones que contienen ibrutinib.

Country Status (29)

Country Link
US (6) US20160287594A1 (enExample)
EP (3) EP3892302B8 (enExample)
JP (4) JP2018513852A (enExample)
KR (2) KR20240013859A (enExample)
CN (2) CN107530293A (enExample)
AU (4) AU2016246669B2 (enExample)
CA (1) CA2981601A1 (enExample)
CL (1) CL2017002512A1 (enExample)
DK (1) DK3892302T3 (enExample)
EA (1) EA033992B1 (enExample)
ES (1) ES2964472T3 (enExample)
FI (1) FI3892302T3 (enExample)
HK (1) HK1250925A1 (enExample)
HR (1) HRP20231207T1 (enExample)
HU (1) HUE063751T2 (enExample)
IL (2) IL295941A (enExample)
LT (1) LT3892302T (enExample)
MA (2) MA54411B1 (enExample)
MD (1) MD3892302T2 (enExample)
MX (2) MX2017012822A (enExample)
PH (1) PH12017501811A1 (enExample)
PL (1) PL3892302T3 (enExample)
PT (1) PT3892302T (enExample)
RS (1) RS64653B1 (enExample)
SG (2) SG11201707989PA (enExample)
SI (1) SI3892302T1 (enExample)
SM (1) SMT202300422T1 (enExample)
UA (1) UA125681C2 (enExample)
WO (1) WO2016164404A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
EP3892302B8 (en) 2015-04-06 2023-10-18 Janssen Pharmaceutica NV Compositions containing ibrutinib
CN109790121B (zh) 2016-10-06 2024-01-05 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
US11576917B2 (en) 2018-01-20 2023-02-14 Natco Pharma Limited Pharmaceutical compositions comprising Ibrutinib
KR20190122561A (ko) * 2018-04-21 2019-10-30 류형준 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물
KR102844084B1 (ko) * 2018-06-15 2025-08-07 얀센 파마슈티카 엔브이 이브루티닙을 포함하는 제형/조성물
GB2591396B (en) 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
US12083222B2 (en) 2018-08-18 2024-09-10 Oncosol Limited Chemotherapeutic pharmaceutical suspension for oral dosage
KR102198502B1 (ko) * 2018-09-16 2021-01-05 류형준 인체의 림프순환 개선을 위한 식품 조성물
JP2022513666A (ja) * 2018-11-30 2022-02-09 ヤンセン バイオテツク，インコーポレーテツド 濾胞性リンパ腫の治療方法
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
KR102251435B1 (ko) * 2020-11-09 2021-05-11 류형준 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
TN2023000295A1 (en) * 2021-06-10 2025-07-02 Hikma Pharmaceuticals Usa Inc Oral dosage forms of ibrutinib
CN117064862B (zh) * 2023-04-10 2025-12-19 山东新时代药业有限公司 一种伊布替尼肠溶片及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK607188A (da) 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
DE10201304A1 (de) 2002-01-15 2003-07-31 Infineon Technologies Ag Nichtflüchtige Halbleiter -Speicherzelle sowie zugehöriges Herstellungsverfahren
WO2006116596A2 (en) * 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compostions containing same
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20140303191A1 (en) * 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
WO2014004707A1 (en) * 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
WO2014142678A1 (en) 2013-03-14 2014-09-18 Fisher & Paykel Healthcare Limited Catheter mount with suction port
CN104119350B (zh) 2013-04-28 2017-04-12 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
CA2920821A1 (en) * 2013-08-12 2015-02-19 The Yokohama Rubber Co., Ltd. Primer composition
CA2920534A1 (en) * 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
WO2015140709A1 (en) 2014-03-19 2015-09-24 Novartis Ag Solid pharmaceutical dosage forms
BR112017001677A2 (pt) 2014-08-01 2018-07-17 Pharmacyclics Llc biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN104407067B (zh) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 依鲁替尼及其异构体的检测方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
EP3892302B8 (en) 2015-04-06 2023-10-18 Janssen Pharmaceutica NV Compositions containing ibrutinib
MX2018014577A (es) 2016-05-27 2019-05-20 Tg Therapeutics Inc Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.

Also Published As

Publication number Publication date
AU2026200996A1 (en) 2026-03-05
AU2016246669A1 (en) 2017-10-12
US20230263804A1 (en) 2023-08-24
CL2017002512A1 (es) 2018-03-16
AU2016246669B2 (en) 2021-07-15
JP2024026087A (ja) 2024-02-28
EP3892302A1 (en) 2021-10-13
MA54411A (fr) 2021-10-13
JP2018513852A (ja) 2018-05-31
KR102632745B1 (ko) 2024-02-01
SMT202300422T1 (it) 2024-01-10
WO2016164404A1 (en) 2016-10-13
EP3892302B8 (en) 2023-10-18
UA125681C2 (uk) 2022-05-18
US20260048055A1 (en) 2026-02-19
IL254695B2 (en) 2023-02-01
US20160287594A1 (en) 2016-10-06
JP2022031690A (ja) 2022-02-22
IL295941A (en) 2022-10-01
AU2024200883A1 (en) 2024-02-29
PH12017501811A1 (en) 2018-04-23
IL254695B (en) 2022-10-01
EP4272835A3 (en) 2023-12-20
FI3892302T3 (fi) 2023-11-03
KR20170134582A (ko) 2017-12-06
SG11201707989PA (en) 2017-10-30
AU2021250925B2 (en) 2023-11-16
MA41901A (fr) 2021-04-14
US12364698B2 (en) 2025-07-22
US20220211713A1 (en) 2022-07-07
CN107530293A (zh) 2018-01-02
EP4272835A2 (en) 2023-11-08
HUE063751T2 (hu) 2024-01-28
BR112017021325A2 (pt) 2018-06-26
SG10202103458QA (en) 2021-05-28
SI3892302T1 (sl) 2023-11-30
MD3892302T2 (ro) 2024-03-31
EP3280446A1 (en) 2018-02-14
MA54411B1 (fr) 2023-11-30
EP3892302B1 (en) 2023-09-06
JP2026116969A (ja) 2026-07-14
US20200171036A1 (en) 2020-06-04
IL254695A0 (en) 2017-11-30
KR20240013859A (ko) 2024-01-30
CN113546054A (zh) 2021-10-26
HK1250925A1 (zh) 2019-01-18
CA2981601A1 (en) 2016-10-13
AU2021250925A1 (en) 2021-11-11
EA201792224A1 (ru) 2018-06-29
US20170252344A1 (en) 2017-09-07
PL3892302T3 (pl) 2024-03-11
EA033992B1 (ru) 2019-12-17
DK3892302T3 (da) 2023-11-13
MX2021015250A (es) 2022-01-24
HRP20231207T1 (hr) 2024-01-19
RS64653B1 (sr) 2023-10-31
LT3892302T (lt) 2023-11-10
JP7438178B2 (ja) 2024-02-26
PT3892302T (pt) 2023-11-15
ES2964472T3 (es) 2024-04-08

Similar Documents

Publication Publication Date Title
MX2021015250A (es) Composiciones que contienen ibrutinib.
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
MX348831B (es) Administración parenteral de tapentadol.
MX2020007554A (es) Formulacion farmaceutica que comprende esomeprazol y bicarbonato de sodio.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PL1994926T3 (pl) Preparaty walsartanu
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
MX2024010837A (es) Composiciones que contienen ibrutinib
WO2013124832A3 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
IN2013MU03610A (enExample)
MX2019005005A (es) Tableta de liberacion extendida que comprende un farmaco de perdida de peso.
WO2019221684A3 (en) The bilayer tablet formulation of fesoterodine
UA91650U (uk) Фармацевтична композиція похідних гамма-аміномасляної кислоти для твердих капсул
MD3770G2 (ro) Metodă de profilaxie a infecţiilor respiratorii virale acute nongripale
MY196892A (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
MY195264A (en) Granules Containing Besifovir Dipivoxil or Pharmaceutically Acceptable Salt Thereof, Pharmaceutical Composition Comprising Granules, And Preparation Method Therefor
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
GR1008380B (el) Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου
GR1008112B (el) Φαρμακευτικο σκευασμα περιεχον εναν εκλεκτικο αγωνιστη των υποδοχεων της σεροτονινης και μεθοδος για την παρασκευη αυτου
IN2014MU01178A (enExample)
PH12017500346A1 (en) Film coated tablet for the treatment of acute pain
GR1007741B (el) Φαρμακευτικο σκευασμα περιεχον εναν ατυπικο αντιψυχωτικο παραγοντα και μεθοδος για την παρασκευη αυτου